RBC Capital raised the firm’s price target on Teladoc (TDOC) to $12 from $11 and keeps an Outperform rating on the shares ahead of its Q4 results. The company’s BetterHelp revenue and trends remain in focus as its user count has declined sequentially over the past five quarters, but the firm’s analysis of app utilization suggests that a positive reversal in this trend may have occurred, the analyst tells investors in a research note. RBC adds that in its recent management meeting, Teladoc said it was seeing improving momentum on the international side of the BetterHelp business and was continuing to accelerate its investments there.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TDOC:
- Teladoc call volume above normal and directionally bullish
- Teladoc price target lowered to $10.50 from $11.50 at BofA
- Study shows online therapy boom mostly benefited priviledged groups, NYT says
- Lilly cuts FY24 outlook, United Rentals to acquire H&E: Morning Buzz
- Unusually active option classes on open January 14th